Clearmind Medicine, a clinical-stage biopharmaceutical company, has been invited to the Frontiers of Mental Health and Recovery Summit in Washington D.C. to discuss advancing non-hallucinogenic psychedelic-derived treatments for mental health and addiction disorders. The company’s Chief of Global Impact will participate in collaborative sessions focused on accelerating system readiness for these therapies and share updates on their investigational drug CMND-100 for Alcohol Use Disorder. This involvement highlights Clearmind's role in shaping future scalable mental health treatments and expanding patient access through existing healthcare systems. The company continues clinical trials at Yale and Johns Hopkins, aiming to offer innovative, cost-effective treatment options.
Clearmind Medicine's invitation to the Washington D.C. Psychedelic Summit is presented here with Pluang's Health sector market data as of Nov 10, 2026 18:42 WIB: Out of 150 priced US Health-sector stocks on Pluang, 85 rose and 56 fell today. Notable movers include Revvity Inc (RVTY) at USD 163.18 with a 1-day change of +1.53%, LifeStance Health Group Inc. (LFST) at USD 14.81 up +1.44%, and Enveric Biosciences Inc (ENVB) at USD 1.46 rising +1.39%.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
